Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2011 16:45 ET | Source: Mateon Therapeutics

ZYBRESTAT(TM) Results Suggest Improvement in Overall Survival in Phase 2/3 Study in Anaplastic Thyroid Cancer

Median Overall Survival Extended by 1.2 Months for ZYBRESTAT Patients One-Year Survival Almost Tripled With ZYBRESTAT Plus Chemotherapy Compared to Chemotherapy Alone (26% vs....
June 06, 2011 08:00 ET | Source: Mateon Therapeutics

OXiGENE Complies With NASDAQ Listing Requirements

SOUTH SAN FRANCISCO, Calif., June 6, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
June 04, 2011 15:00 ET | Source: Mateon Therapeutics

OXiGENE Reports Encouraging Data From Phase 2 Trial of ZYBRESTAT(TM) in Non-small Cell Lung Cancer

SOUTH SAN FRANCISCO, Calif., June 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
May 18, 2011 08:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Clinical Data From FACT and FALCON Studies to be Presented at ASCO

SOUTH SAN FRANCISCO, Calif., May 18, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
May 12, 2011 16:00 ET | Source: Mateon Therapeutics

OXiGENE Reports First Quarter 2011 Financial Results

SOUTH SAN FRANCISCO, Calif., May 12, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
May 12, 2011 08:00 ET | Source: Mateon Therapeutics

OXiGENE Announces Initiation of Phase 1 Trial of OXi4503 in Patients With Acute Myelogenous Leukemia and Myelodysplastic Syndrome

OXi4503 is a Novel, Dual-Action Vascular Disrupting Agent The Leukemia & Lymphoma Society to Provide Study Support SOUTH SAN FRANCISCO, Calif., May 12, 2011 (GLOBE NEWSWIRE) -- OXiGENE,...
May 06, 2011 08:00 ET | Source: Mateon Therapeutics

OXiGENE Announces First Quarter 2011 Earnings Conference Call and Webcast

SOUTH SAN FRANCISCO, Calif., May 6, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
April 11, 2011 08:17 ET | Source: Mateon Therapeutics

OXiGENE Announces First Patient Enrolled in Phase 2 Study of ZYBRESTAT in Patients With Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., April 11, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
April 04, 2011 08:00 ET | Source: Mateon Therapeutics

OXiGENE'S Novel Cathepsin L Inhibitors Demonstrate Antitumor Efficacy in Preclinical Studies

SOUTH SAN FRANCISCO, Calif., April 4, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...
March 21, 2011 08:00 ET | Source: Mateon Therapeutics

OXiGENE Receives Meeting Minutes from FDA Type C Meeting on ZYBRESTAT(TM) Anaplastic Thyroid Program

SOUTH SAN FRANCISCO, Calif., March 21, 2011 (GLOBE NEWSWIRE) -- OXiGENE, Inc. (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases,...